The estimated Net Worth of Edward F Smith is at least $2.14 Millón dollars as of 9 March 2021. Mr. Smith owns over 40,356 units of Marinus Pharmaceuticals Inc stock worth over $18,470 and over the last 10 years he sold MRNS stock worth over $876,353. In addition, he makes $1,247,750 as Chief Financial Officer at Marinus Pharmaceuticals Inc.
Edward has made over 5 trades of the Marinus Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 40,356 units of MRNS stock worth $718,337 on 9 March 2021.
The largest trade he's ever made was selling 40,356 units of Marinus Pharmaceuticals Inc stock on 9 March 2021 worth over $718,337. On average, Edward trades about 4,024 units every 63 days since 2014. As of 9 March 2021 he still owns at least 13,288 units of Marinus Pharmaceuticals Inc stock.
You can see the complete history of Mr. Smith stock trades at the bottom of the page.
Edward F. Smith serves as Chief Financial Officer of the Company. Mr. Smith served as a financial advisor in a consulting capacity for TetraLogic Pharmaceuticals Corporation (OTCMKTS: TLOG), which voluntary filed for Chapter 7 bankruptcy on April 1, 2013 . From January 2006 to April 2013, Mr. Smith served as Chief Financial Officer of PolyMedix, Inc., a company engaged in the development of small-molecule drugs for the treatment of serious acute care conditions, which voluntarily filed for chapter 7 bankruptcy on April 1, 2013. From September 2000 to December 2005, Mr. Smith was Executive Director of Finance at InKine Pharmaceutical Company, Inc., a biopharmaceutical company focused on the diagnosis and treatment of gastrointestinal disorders. Earlier in his career, Mr. Smith held various positions of increasing responsibility in public accounting, most recently as a manager in the audit practice at Deloitte & Touche, LLP. Mr. Smith is currently on the board of directors at Benitec Biopharama, Inc. (Nasdaq: BNTC). Mr. Smith was licensed as a Certified Public Accountant in Pennsylvania and holds a BS in Business Administration from the University of Hartford.
As the Chief Financial Officer of Marinus Pharmaceuticals Inc, the total compensation of Edward Smith at Marinus Pharmaceuticals Inc is $1,247,750. There are 1 executives at Marinus Pharmaceuticals Inc getting paid more, with Scott Braunstein having the highest compensation of $2,245,680.
Edward Smith is 47, he's been the Chief Financial Officer of Marinus Pharmaceuticals Inc since 2020. There are 14 older and no younger executives at Marinus Pharmaceuticals Inc. The oldest executive at Marinus Pharmaceuticals Inc is Martha E. Manning, 66, who is the VP, Gen. Counsel & Sec..
Edward's mailing address filed with the SEC is C/O BENITEC BIOPHARMA INC., 3940 TRUST WAY, HAYWARD, CA, 94545.
Over the last 10 years, insiders at Marinus Pharmaceuticals Inc have traded over $13,562,679 worth of Marinus Pharmaceuticals Inc stock and bought 2,520,427 units worth $19,488,416 . The most active insiders traders include Nicole Vitullo, Capital Life Sciences Inves... y Anand Mehra. On average, Marinus Pharmaceuticals Inc executives and independent directors trade stock every 68 days with the average trade being worth of $149,293. The most recent stock trade was executed by Christina Shafer on 5 August 2024, trading 3,820 units of MRNS stock currently worth $4,355.
marinus pharmaceuticals is a clinical stage biopharmaceutical company dedicated to positively impacting the well-being of patients who suffer from epilepsy and neuropsychiatric disorders. the company is in the midst of developing and commercializing ganaxolone which will treat adults and children with epileptic seizures and women with postpartum depression. on june 29, 2017, the company announced that the u.s. food and drug administration (fda) granted orphan drug designation to ganaxolone for the treatment of cdkl5 disorder. cdkl5 disorder is a severe, rare genetic disorder that affects children at an early age and causes difficult-to-control seizures and neuro-developmental impairment. currently, there are no approved therapies for children with cdkl5 disorder. orphan drug designation is granted by the fda office of orphan products development to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the u.s. the designation provides
Marinus Pharmaceuticals Inc executives and other stock owners filed with the SEC include: